4-5th November 2019,  2-Day workshop:

Network meta-analysis and population adjustment for decision-making 

Presented by David Phillippo at the Macquarie University Sydney Campus

 

Day 1:

  • Day 1 of this course is aimed at statisticians, health economists, decision-makers, and systematic reviewers who are already familiar with pairwise meta-analysis, and who want to extend their knowledge to NMA and population adjustment methods. Participants will develop an understanding of these methods and the required assumptions and learn to assess and critique these types of analyses.

Day 2:

  • Day 2 is aimed at those with technical experience of meta-analysis who want to apply the knowledge learned on Day 1 to hands-on practical examples. Participants will gain experience implementing NMA and population-adjusted analyses in an R package based on the Bayesian modelling language Stan.

Network meta-analysis (NMA) is a method for combining evidence from several studies on multiple treatments of interest to provide a consistent set of relative effect estimates and is widely used for healthcare decision-making and guideline development. More recently, population adjustment methods have been proposed that use individual patient data from one or more studies to relax the assumptions of NMA and adjust for differences in effect modifying variables between populations, or even to incorporate disconnected networks and single-arm studies. The methods are becoming increasingly common in technology appraisal submissions to reimbursement agencies and raise new questions and challenges for analysts anddecision-makers.

Our workshop presenter is David Phillippo, a Senior Research Associate in Statistics at the University of Bristol, UK. His research focuses on methodology for evidence synthesis, Bayesian Network Meta-Analysis (NMA), population adjustment methods for indirect comparisons, and accounting for bias in clinical guidelines. He is the lead author of a recent Technical Support Document published by the NICE Decision Support Unit on population-adjusted indirect comparisons, and has developed new methods extending the NMA framework to incorporate population adjustment combining individual patient data and published summary data.

For more information and to register, please click https://statsoc.org.au/event-3334476

15th August:FREE Statistics Mid-Year seminar - Hurry Places are limited

When: 15 August 2019, presentations go from 1pm-4pm

Where: Eli Lilly and Company, 112 Wharf Road, West Ryde

 

Topics:

1. Reflections of a statistician on health economic modelling in the Australian context. 

Manjula Schou (Biostatistician /Research Fellow, Janssen-Cilag/Department of Mathematics and Statistics at Macquarie University, Sydney)

Manjula Schou has over 20 years of experience working as a statistician, predominantly in the pharmaceutical industry. She currently splits her time between Janssen-Cilag where she works within the Health Economics, Outcomes Research and Pricing team as a health economic modeller and company wide statistician, and the Department of Mathematics and Statistics at Macquarie University as a Research Fellow. In her later capacity Manjula's research interests are mainly focused on clinical trials methodology and statistical methods for health economic modelling. 

2. The application of machine learning to personalise the care and treatment of substance use disorders.

Chrianna Bharat (Biostatistician, PhD Candidate ,National Drug & Alcohol Research Centre, Sydney)

Chrianna Bharat is a PhD Candidate at the National Drug and Alcohol Research Centre, UNSW Sydney. Chrianna’s research project focuses on the use of routinely collected data to develop predictive models to optimise treatment outcomes among people with alcohol and drug problems. After receiving her bachelor’s degree with Honours in applied statistics from the University of Western Australia, Chrianna worked as a statistical consultant for the Centre of Applied Statistics. For the past three years, Chrianna’s role as biostatistician for the Substance Use Disorder (SUD) Workgroup of the World Mental Health Survey Initiative has seen her analysing complex survey data to determine the prevalence, risk factors and treatment needs for SUDs. 

Substance use disorders (SUDs) are a major contributor to the global burden of disease. Recently, the United Nations marked strengthening the prevention and treatment of SUDs as a public health priority. With machine learning methods increasingly being applied to healthcare data to support the delivery of personalised medicine, there exists the potential to use these methods to improve the processes of detecting, classifying and treating SUDs. The development of machine learning algorithms to predict SUD onset and treatment outcomes could facilitate the implementation of targeted prevention, increase SUD treatment coverage and personalise treatment allocation.

This presentation will provide a brief overview of machine learning applications in the field of alcohol and drug use disorders and describe the application of a machine learning algorithm for predicting individuals at high risk of developing an alcohol use disorder.


3. Some insights on state of the art of evidence synthesis.(Advances in meta-analysis) 

Gian Luca Di Tanna (Head of Statistics Australia at the George Institute for Global Health, Sydney)

Dr Gian Luca Di Tanna is currently the Head of Statistics Australia at the George Institute for Global Health in Sydney. He has an Honours in Statistics along with a Post-graduate specialization in Medical Statistics and has obtained an MSc in Data Intelligence & Decision Making and a PhD in Health economics (Catholic University of the Sacred Heart, Italy). His Academic positions include the Sapienza University of Rome, London School of Hygiene and Tropical Medicine and the Queen Mary University of London. Dr Gian Luca Di Tanna has worked until March 2019 as a Global Health Economics Senior Manager at the Economic Modelling Centre for Excellence for Amgen, Switzerland and is affiliated with the Riskcentre - Dept. of Econometrics, Statistics and Applied Economics at the University of Barcelona, Spain. He is on the Editorial Board of the journal PharmacoEconomics, Statistical Editor of the Consumers and Communication Cochrane group and member of the Cochrane Methods Group in Systematic Reviews and Meta Analysis.

I take the opportunity of this talk to comment on the current trends in systematic reviews and highlight “established” statistical methods for meta analysis with a particular focus on some issues/assumptions that go commonly overlooked. I will illustrate the various types of meta analysis (aggregate and individual patient data, head-to-head and network meta analysis), how to deal with different study designs and discuss potential misconceptions and warnings.

Please RSVP if you plan to attend for catering purposes & entry to the building – by 26 July to myself at  alan_brnabic@lilly.com

>  2015. The use of modern causal inference methods in analysing RCTs Workshop.

Presenter: Dr Richard Emsley (Centre for Biostatistics, Institute of Public Health,
University of Manchester, UK)

 

Location:  MGSM conference centre at 37 Pitt St in the CBD in Sydney

Date:  6th December 2015

Time: TBD

 

This talk will be from 4:30pm to 5:30pm, at the MGSM conference centre at 37 Pitt St in the CBD in Sydney. We will be heading to dinner afterwards with the speaker if you would like to join also (at your own expense).

Prior to the talk we will be holding our AGM (from 3:30, afternoon tea from 3pm). If you are, or would like to become an APBG member, we would love for you to attend this also.  APBG members must work in the regulated healthcare area in statistics or a related field – please let us know if you would like to join.

Please RSVP to myself indicating if you will be attending the talk, the AGM or both.

For more information on the APBG (including the slides from the event you attended) please visit our website http://apbgroup.squarespace.com

>  2015. DMC Workshop.
Presenter: Dr Simon Day


Location:  CBD , Sydney. TBD

Date:  26-27th February 2015

 

Course Description: The course is relevant to all those (statisticians and non-statisticians) who need to set up DMCs and work with them throughout the course of a clinical trial.  It is also relevant to those who may serve as members of DMCs. It will focus on practical issues around the workings of data monitoring committees (DMCs) including a review of group sequential methods and FDA and CHMP guidance on DMCs. Throughout the course, mock DMC sessions will be convened where various scenarios will be considered and discussed, and decisions have to be made.

>  2014. APBG AGM

Location: Room 23, Level 4, Building 2, UTS - Room 2.4.23. 15 Broadway, Ultimo, NSW, 2007

Date: Tuesday 28 October 2014

Time: 5pm-6pm then


Talk by Professor John Carlin, Murdoch Children’s Research Institute & The University of Melbourne

Talk Topic : Assessing the risk of a rare adverse outcome following rotavirus vaccination: a case study in biostatistical methods and collaborative engagement

 

Location: Room 6, Level 4, Building 2, UTS Tower building- Room 2.4.6. 15 Broadway, Ultimo, NSW, 2007

Date: Tuesday 28 October 2014

Time: 6:30pm-7.30pm (Refreshments from 6pm)

 

>  2014 Do pharmacological interventions reduce drugs-related deaths ?

Speaker, Professor Sheila M Bird. MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK

 

Date: 2nd July 2014

Time: 6-7.30pm

Venue: The Sebel Hotel. 28 Albion St Sydney 2012

 

 

PAST

 

>  2012.  Mixed Treatment Comparisons

Date: 4th 5th June 2012

Venue:MGSM Executive Hotel and Conference Centre. 99 Talavera Rd, Macquarie Park 2113 Tel. 02 9850 9082


Details: This workshop on Mixed Treatment Comparisons (MTC) is proudly supported by the Australian Pharmaceutical Biostatistics Group (APBG) and the Statistical Society of Australia (SSAI).
The workshop utilises the expertise of Professor George Wells form the Department of Epidemiology and Community Medicine Director, University of Ottawa Heart Institute.

Day 1 will be a high level overview on MTCs and their applications. There will be demonstrations of worked examples using SAS and Win BUGs. A brief outline includes: Introduction to indirect treatment comparisons Network meta-analysis methods

     Part 1: Bucher approach and the Frequentist network meta-analysis - general linear mixed models Network meta-analysis methods

     Part 2: Bayesian network meta-analysis - mixed treatment comparisons Worked example - Bayesian network meta-analysis Worked example -  
     Frequentist network meta-analysis


Day 2: will be more practical hands on session with applications of what was taught in Day 1.
There will be several breakout sessions where groups will work through examples and present back.
The day will conclude with limitations and future research.

Programs: Detailed Program Registrations: Register from SSAI Website

 

 

> 2011.  Adaptive Designs for clinical trials

Date: 6-7th April 2011

Venue: MGSM Executive Hotel and Conference Centre. 99 Talavera Rd, Macquarie Park 2113 Tel. 02 9850 9082

 

Details: This workshop on adaptive design is proudly supported by the Australian Pharmaceutical Biostatistics Group (APBG), the Statistical Society of Australia (SSAI) and the George Institute.This workshop takes advantage of Dr Brenda Gaydos’ visit to Australia. Brenda is the Eli-Lilly specialist in adaptive designs, has a wealth of experience to share and has written several papers including one on Good Clinical Practice in this area. She will team-up with two leading researchers in adaptive designs, Dr Patrick Kelly of Sydney University, and Dr Frank Bretz of Novartis, Switzerland. Frank is an adjunct professor of the University of Hannover (Germany), and has published more than 100 papers and two books on multiplicity issues.

 

Programs: Detailed Program Registrations: Register from SSAI Website

 

 

> 2009.  Challenges of running oncology clinical trials

Date: Thursday, 26 November 2009

Venue: Coles Theatre, School of Business, University of Melbourne, Australia

Details: This workshop is your opportunity to share your experiences and challenges of working on clinical trials in oncology. The workshop aims to take you through some of the stages during the execution of a clinical trial in oncology. It will start with discussions around developing concept outlines and protocols for oncology studies, the designs of oncology clinical trials and the subsequent logistics from a statistical, monitoring and data management perspective. From there the focus will move to safety reporting and the use of data safety monitoring boards, the differences between MedDRA and CTC coding dictionaries and why you would use one rather than the other followed by how the TGA reviews oncology studies. After lunch the discussions will become more specific around the types of measures and the corresponding analyses and the benefits and pitfalls of using the RECIST criteria. The day will finish with some ideas on how to undertake a critical appraisal of the oncology literature and a look into the future promises and challenges of oncology studies with the exciting novel therapies.

 

Programs: Detailed Programs Registrations: Register from SSAI Website

 

 

> 2009.  ARCS 18th Annual Scientific Congress: Education into Practice

Date: 1-3 June 2009

Venue: Sydney Convention and Exhibition Centre, Australia

Details: The ARCS ASC is the premier Australian event for those involved in the development of therapeutic goods. With the theme "Education Into Practice" the 2009 ASC is focused on ensuring the transfer of knowledge into practice, with tangible take-home messages to improve professional performance.

 


>2008.  Statistical estimates of benefits and hazards of Hormonal Therapy post-menopause: reconciling observational and trial data

Date: Wednesday, 22 October 2008

Venue: Lecture Room 2.4.11, Building 2, University of Technology Sydney, Broadway, Sydney

Details: http://apbgroup.squarespace.com/documents-public/Monthly%20Notice%20-%202008%20Oct.pdf

 


> 2008.  Australian Statistical Conference 2008

Date: 30 June - 3 July 2008

Venue: Sofitel Melbourne, Melbourne

Details: http://www.asc2008.com.au/

 

 

>2008.  From randomised trials to national policy decisions via cost-effectiveness analysis

Date: 8 July 2008

Venue: Pfizer Auditorium, 38-42 Wharf Rd, West Ryde, Sydney

Details: http://www.apbg.org.au/documents-public/Monthly%20Notice%20-%20ST_July08.pdf

 


> 2008.  Bayesian Methods in Health Economics

Date: 14 - 16 July 2008

Venue: TBC, Sydney

Details: http://www.arcs.com.au/documents/Bayesian_Syd_14Jul08.pdf
 

 

> 2008.  Workshop on integrating statistical ideas into mathematics

Date: 6 August 2008

Venue: Macquarie Graduate School of Management Conference Centre NSW

Details: SSAI Flyer Indirect Comparison Workshop [2007] The notes for the workshop can be downloaded here. 9.00 am


Session 1: Introduction to Indirect Comparisons - Philip McCloud 10.30 am

Session 2: Design and Interpretation Issues - Philip McCloud 11.00 am

Session 3: The use of Indirect comparisons to compliment RCT evidence – Bill Montgomery & Kristina Coleman 11.30 am

Session 4: Are all comparators Identical? - Philippa Clarke 1.00 pm

Session 5: Sources of Variation: fixed or random? - Philip McCloud 1.30 pm

Session 6: Random effects and Bayesian Methods – Patrick Fitzgerald 3.00 pm
Session 7: Double Comparators: twice the fun? - Annie Solterbeck

 

  • LinkedIn Social Icon
  • w-facebook
  • Twitter Clean
  • Google+ Clean

© 2015 APBG Australian Pharmaceutical Biostatistic Group.  Proudly created with Wix.com

 

Copyright Notice

Copyright on all material on this website is owned by APBG unless otherwise indicated. APBG authorises you to copy any material published by APBG placed on this Website for non-commercial use only, provided that any copied material from the Website retains all copyright or other proprietary notices and any disclaimer contained thereon.

APBG makes no representation as to the accuracy or any other aspect of the information contained on servers linked to the Website via hyperlinks from APBG Website.

 

Disclaimer Notice

The content of APBG's Website is provided for information purposes only. APBG makes no claim as to the accuracy of the content contained in the Website. APBG does not accept liability to any person for the information or advice provided on this Website or incorporated into it by reference. APBG does not accept liability for loss or damages incurred by any person as a result of reliance upon the content of this Website or any other information incorporated by reference.

This information is provided on the basis that all persons accessing the Website undertake the responsibility for assessing the accuracy of its content and that they rely on it entirely at their own risk.